How simpler implementations enable complex cell and gene therapies
After spending 12 years working in the biopharmaceutical industry – three of those here at Vineti – I’ve learned first-hand that cell and gene therapies…
New FDA guidance: cell therapies and patient identifiers
When the US Food and Drug Administration (FDA) recently made two draft guidance documents for the cell and gene therapies available for comment, the Vineti…
Cell and gene therapies: the necessity of a purpose-built platform
Given the wide array of CRMs and other digital systems already serving healthcare and biopharma, that reality might sound like overkill. But after more than…
Vineti secures new patent from USPTO for individualized medicine platform
SAN FRANCISCO, March ##, 2022 (GLOBE NEWSWIRE) – Vineti, Inc., the provider of the leading digital platform of record for cell and gene therapies, today…
Vineti’s Personalized Therapy Management® (PTM) solution meets rigorous standards: Service Organization Control (SOC®) 2 Type II compliance audit
Vineti, developer of the leading digital platform of record for personalized therapeutics, today announced a new Integration Suite as a cornerstone of its Personalized Therapy…
Vineti introduces new PTM® Integration Suite: purpose-built connectivity and interoperability for cell and gene therapies
Vineti, developer of the leading digital platform of record for personalized therapeutics, today announced a new Integration Suite as a cornerstone of its Personalized Therapy…
Why an integrated, digital cell and gene therapy (CGT) ecosystem protects patients and their privacy
Cell and gene therapies (CGTs) are modern, technologically advanced therapies that rely on a complex value chain for manufacturing and patient treatment. Patients are at…
Why CGT 3.0 success depends on interoperability
The cutting edge therapies of CGT 3.0 require modern operations. That means far more than just stand-alone digital systems and select integrations — it means…
How integrated digital systems solve key challenges with cell and gene therapies (CGTs)
One patient. One cell therapy. Ten or more distinct digital systems.
That’s often the number of heterogeneous digital systems across care sites, manufacturers, and…
Be The Match BioTherapies® and Vineti collaborate to develop innovative, integrated supply chain management solutions for cell and gene therapies
MINNEAPOLIS, Minn. and SAN FRANCISCO, Calif, December 08, 2021 - Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and…
Preparing for Cell and Gene Therapy 3.0
Patient data is mission-critical data — especially in cell and gene therapy.
In cell and gene therapy (CGT), the patient is the process is the…
Patient data – the unique role in cell and gene therapies (CGTs)
Patient data is mission-critical data — especially in cell and gene therapy.
In cell and gene therapy (CGT), the patient is the process is the…